PLA2R Antibody Does Not Outperform Conventional Clinical Markers in Predicting Outcomes in Membranous Nephropathy

Beck, 2009, M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy, N Engl J Med, 361, 11, 10.1056/NEJMoa0810457 Zucchelli, 1987, Long-term outcome of idiopathic membranous nephropathy with nephrotic syndrome, Nephrol Dial Transplant, 2, 73 Torres, 2002, Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy, Kidney Int, 61, 219, 10.1046/j.1523-1755.2002.00124.x Kanigicherla, 2016, Long-term outcomes of persistent disease and relapse in primary membranous nephropathy, Nephrol Dial Transplant, 31, 2108, 10.1093/ndt/gfv435 2021, Kidney disease: improving global outcomes (KDIGO) glomerular diseases work group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases, Kidney Int, 100, S1, 10.1016/j.kint.2021.05.021 Bobart, 2019, Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies, Kidney Int, 95, 429, 10.1016/j.kint.2018.10.021 Bobart, 2021, Non invasive diagnosis of PLA2R-associated membranous nephropathy: a validation study, Clin J Am Soc Nephrol, 16, 1833, 10.2215/CJN.05480421 Hoxha, 2014, Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, J Am Soc Nephrol, 25, 1357, 10.1681/ASN.2013040430 Ruggenenti, 2015, Anti-phospholipase A2 receptor antibody titre predicts post-rituximab outcome of membranous nephropathy, J Am Soc Nephrol, 26, 2545, 10.1681/ASN.2014070640 Liu, 2016, Detection and clinical significance of glomerular M-type phospholipase A2 receptor in patients with idiopathic membranous nephropathy: glomerular PLA2 R in patients with IMN, Intern Med J, 46, 1318, 10.1111/imj.13233 Wang, 2017, Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study, BMC Nephrol, 18, 227, 10.1186/s12882-017-0636-0 Zhang, 2018, Clinical and histological features of phospholipase A2 receptor-associated and thrombospondin type-I domain-containing 7A-associated idiopathic membranous nephropathy: a single-center retrospective study from China, Med Sci Monit Int Med J Exp Clin Res, 24, 5076 Wu, 2018, The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy: a meta-analysis, Medicine, 97 Liang, 2019, Serum anti-phospholipase A2 receptor (PLA2R) antibody detected at diagnosis as a predictor for clinical remission in patients with primary membranous nephropathy: a meta-analysis, BMC Nephrol, 20, 360, 10.1186/s12882-019-1544-2 Jurubiță, 2021, Clinical phenotypes and predictors of remission in primary membranous nephropathy, J Clin Med, 10, 2624 Logt, 2021, Anti-PLA2R1 antibodies as prognostic biomarker in membranous nephropathy, Kidney Int Rep, 6, 1677, 10.1016/j.ekir.2021.04.002 Dahan, 2017, Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up, J Am Soc Nephrol, 28, 348, 10.1681/ASN.2016040449 Kanigicherla, 2013, Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy, Kidney Int, 83, 940, 10.1038/ki.2012.486 Hoxha, 2011, An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis, Nephrol Dial Transplant, 26, 2526, 10.1093/ndt/gfr247 Hofstra, 2012, Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy, J Am Soc Nephrol, 23, 1735, 10.1681/ASN.2012030242 Qin, 2016, Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy, J Am Soc Nephrol, 27, 3195, 10.1681/ASN.2015080953 Sethi, 2021, New “antigens” in membranous nephropathy, J Am Soc Nephrol, 32, 268, 10.1681/ASN.2020071082